However, the sensitivities of both mSEPT9 and CEA were low (<27.6%) in patients with adenoma, both advanced and non-advanced, and there was no significant difference in positive rates between mSEPT9 and CEA for patients with adenoma. The gene discussed is CEACAM5; the disease is adenoma.